NIHR Signal: Eplerenone does not improve vision in people with central serous chorioretinopathy (CSC)

Expert commentary is provided for a trial of 114 adults with CSC for ≥4 months, without any previous treatment, which found eplerenone was not associated with any clinically important or statistically significant difference to placebo in terms of visual acuity at 12 months.


NIHR Dissemination Centre